| Recruiting | Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation | Phase 1 / Phase 2 | 2026-03-01 |
| Recruiting | Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation | Phase 1 / Phase 2 | 2025-10-29 |
| Recruiting | DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lun Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease | — | 2025-01-23 |
| Recruiting | Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETO Progressive Pulmonary Fibrosis, Interstitial Lung Disease | Phase 3 | 2023-10-30 |
| Recruiting | Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection Interstitial Lung Disease, Pulmonary Hypertension | — | 2023-08-11 |
| Terminated | Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin Pulmonary Arterial Hypertension | — | 2023-07-05 |
| Active Not Recruiting | A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Rev Pulmonary Arterial Hypertension | Phase 4 | 2022-10-20 |
| Completed | Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibro Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | Phase 3 | 2022-10-04 |
| Enrolling By Invitation | Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis | Phase 3 | 2022-09-06 |
| Completed | Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease | Phase 3 | 2021-06-01 |
| Terminated | A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH PAH, Pulmonary Hypertension, Hypertension | Phase 3 | 2021-01-20 |
| Terminated | A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for B Bronchopulmonary Dysplasia | Phase 1 | 2019-10-09 |
| Enrolling By Invitation | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Exten PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension | Phase 3 | 2019-09-23 |
| Completed | Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Usin Pulmonary Arterial Hypertension | Phase 1 | 2019-09-17 |
| Completed | Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH Pulmonary Arterial Hypertension | — | 2019-04-01 |
| Completed | EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypert Pulmonary Arterial Hypertension | Phase 4 | 2019-01-31 |
| Terminated | Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease | Phase 3 | 2018-12-21 |
| Completed | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension | Phase 3 | 2018-08-30 |
| Terminated | A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulm Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease | Phase 3 | 2018-05-08 |
| Terminated | Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF Pulmonary Hypertension Associated With HFpEF | Phase 3 | 2018-01-30 |
| Withdrawn | Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan Pulmonary Arterial Hypertension | Phase 3 | 2017-10-01 |
| Terminated | Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejectio Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction | Phase 3 | 2017-08-15 |
| Active Not Recruiting | ADAPT - A Patient Registry of the Real-world Use of Orenitram® Pulmonary Arterial Hypertension | — | 2017-07-18 |
| Withdrawn | Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associ Pulmonary Hypertension Associated With Sickle Cell Disease | Phase 3 | 2017-06-01 |
| Completed | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Can Small Cell Lung Cancer | Phase 2 / Phase 3 | 2017-06-01 |
| Withdrawn | An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmona Pulmonary Arterial Hypertension | Phase 4 | 2017-06-01 |
| Withdrawn | Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH Pulmonary Arterial Hypertension | Phase 2 | 2017-05-01 |
| Withdrawn | Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease | Phase 2 | 2017-04-01 |
| Completed | Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema | Phase 2 / Phase 3 | 2017-02-03 |
| Withdrawn | Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titr Pulmonary Arterial Hypertension | Phase 4 | 2017-02-01 |
| Terminated | An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema | Phase 2 / Phase 3 | 2016-09-15 |
| Terminated | Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients Neuroblastoma | — | 2016-03-15 |
| Withdrawn | Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis Pulmonary Hypertension, Pulmonary Fibrosis | Phase 2 | 2016-02-01 |
| Terminated | Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn Persistent Pulmonary Hypertension of the Newborn | Phase 2 | 2015-07-29 |
| Completed | Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension Pulmonary Arterial Hypertension | Phase 2 | 2015-07-08 |
| Completed | Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years PAH | Phase 2 | 2014-12-18 |
| Completed | Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension Pulmonary Arterial Hypertension | Phase 2 | 2014-12-01 |
| Completed | Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers Healthy | Phase 1 | 2014-09-01 |
| Withdrawn | Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Health PAH | Phase 1 | 2014-07-01 |
| Completed | An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension Pulmonary Arterial Hypertension | Phase 3 | 2013-09-11 |
| Completed | A Pharmacokinetic Substudy of the TDE-PH-304 Protocol Pulmonary Arterial Hypertension | Phase 3 | 2013-08-01 |
| Terminated | Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH) Pulmonary Arterial Hypertension | Phase 1 | 2013-04-01 |
| Completed | Tyvaso Dosing and Titration Evaluation: TyTRATE Registry Pulmonary Arterial Hypertension | — | 2013-01-01 |
| Completed | ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma Neuroblastoma | Phase 1 / Phase 2 | 2012-08-01 |
| Completed | Three Times Daily Dosing of UT-15C Healthy | Phase 1 | 2012-07-01 |
| Completed | Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy Pulmonary Arterial Hypertension | Phase 3 | 2012-06-26 |
| Withdrawn | Safety and Efficacy of Inhaled Treprostinil in Patients With PAH Pulmonary Arterial Hypertension | Phase 3 | 2012-06-01 |
| Withdrawn | Inhaled Treprostinil for PAH: Open-label Extension Pulmonary Arterial Hypertension | Phase 3 | 2012-06-01 |
| Completed | Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID) Pulmonary Arterial Hypertension | Phase 4 | 2012-04-01 |
| Completed | Remodulin® to Oral Treprostinil Transition Pulmonary Arterial Hypertension | Phase 2 | 2012-04-01 |
| Completed | Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso® Pulmonary Arterial Hypertension | Phase 2 | 2011-10-01 |
| Completed | A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension | — | 2011-01-01 |
| Completed | Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PA Pulmonary Arterial Hypertension | — | 2010-12-01 |
| Completed | A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunt Pulmonary Arterial Hypertension | Phase 1 | 2010-08-01 |
| Completed | Comparative Bioavailability of Treprostinil Diethanolamine Manufactured by Two Independent Facilities Pulmonary Arterial Hypertension | Phase 1 | 2010-07-01 |
| Completed | Pharmacokinetic Linearity and Comparative Bioavailability of Treprostinil Diethanolamine Pulmonary Arterial Hypertension | Phase 1 | 2010-07-01 |
| Completed | The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil Pulmonary Arterial Hypertension, Renal Dysfunction | Phase 1 | 2010-05-01 |
| Completed | A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension Pulmonary Hypertension | Phase 2 | 2010-04-01 |
| Completed | Effect of Food on the Pharmacokinetics of Oral Treprostinil Hypertension, Pulmonary, Pulmonary Arterial Hypertension | Phase 1 | 2009-09-01 |
| Completed | Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil Hypertension, Pulmonary, Pulmonary Arterial Hypertension | Phase 1 | 2009-09-01 |
| Terminated | Open-Label Study of Oral Treprostinil in Digital Ulcers Systemic Sclerosis | Phase 2 | 2009-09-01 |
| Terminated | A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid Primary Refractory Neuroblastoma | Phase 2 | 2009-08-01 |
| Completed | Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension Pulmonary Hypertension | Phase 3 | 2009-06-01 |
| Completed | Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine Systemic Sclerosis, Scleroderma | Phase 2 | 2009-05-01 |
| Completed | Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis Systemic Sclerosis | Phase 1 | 2008-12-01 |
| Withdrawn | FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodies Pulmonary Hypertension | Phase 3 | 2008-12-01 |
| Completed | Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmona Pulmonary Arterial Hypertension | Phase 4 | 2008-09-01 |
| Withdrawn | Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients Liver Transplant | Phase 2 / Phase 3 | 2008-06-01 |
| Terminated | Rapid Switch From Flolan to Remodulin in the Outpatient Clinic Hypertension, Pulmonary | Phase 4 | 2008-03-01 |
| Terminated | Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction Hypertension, Pulmonary | Phase 4 | 2007-03-01 |
| Terminated | Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulator Pulmonary Arterial Hypertension | Phase 4 | 2007-02-01 |
| Completed | An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertensio Pulmonary Arterial Hypertension | Phase 3 | 2007-01-16 |
| Completed | FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiest Pulmonary Hypertension | Phase 3 | 2006-10-01 |
| Completed | FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH) Pulmonary Hypertension | Phase 3 | 2006-10-01 |
| Completed | Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodul Pulmonary Hypertension | Phase 4 | 2006-09-01 |
| Completed | TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertensi Pulmonary Arterial Hypertension | Phase 4 | 2005-06-10 |
| Completed | Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertensio Pulmonary Hypertension | Phase 3 | 2005-06-01 |
| Terminated | Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension Pulmonary Arterial Hypertension | Phase 4 | 2005-03-01 |
| Unknown | 12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Inter Hepatitis C | Phase 2 | 2003-07-01 |
| Terminated | Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft Peripheral Vascular Disease | Phase 2 / Phase 3 | 2003-03-01 |
| Terminated | Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures Critical Limb Ischemia, Peripheral Vascular Disease, Foot Ulcers | Phase 3 | 2003-02-01 |
| Completed | A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension Pulmonary Arterial Hypertension, Pulmonary Hypertension | Phase 4 | 2002-10-01 |
| Completed | Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension Pulmonary Hypertension | Phase 3 | 1998-10-01 |